Abstract
The novel coronavirus (COVID-19) has spread to almost all countries in the world, claiming more than 160,000 lives and sickening more than 2,400,000 people by April 21, 2020. There has been research showing that on average, each infected person spreads the infection to more than two persons. Therefore the majority of the population is at risk of infection if no intervention measures were undertaken. The true size of the COVID-19 epidemic remains unknown, as a significant proportion of infected individuals only exhibit mild symptoms or are even asymptomatic. A timely assessment of the evolving epidemic size is crucial for resource allocation and triage decisions. In this article, we modify the back-calculation algorithm to obtain a lower bound estimate of the number of COVID-19 infected persons in China outside the Hubei province. We estimate the infection density among infected and show that the drastic control measures enforced throughout China following the lockdown of Wuhan City effectively slowed down the spread of the disease in two weeks. Our findings from China are expected to provide guidelines and enlightenment for surveillance and control activities of COVID-19 in other countries around the world.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yukun Liu was supported by the National Natural Science Foundation of China (11771144), the State Key Program of National Natural Science Foundation of China (71931004), the development fund for Shanghai talents, the 111 project (B14019), and the Fundamental Research Funds for the Central Universities. Yan Fan was supported by the National Natural Science Foundation of China (11971300) and Natural Science Foundation of Shanghai. Yong Zhou research was supported by the State Key Program of National Natural Science Foundation of China (71931004), the State Key Program in the Major Research Plan of National Natural Science Foundation of China (91546202).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* co-first authors
Data Availability
The National Health Commission of the People's Republic of China has published daily numbers of confirmed cases of COVID-19 since January 20, 2020; see http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml for all news releases.
